E2F1-initiated transcription of PRSS22 promotes breast cancer metastasis by cleaving ANXA1 and activating FPR2/ERK signaling pathway.
Lin SongHui LiRan-Ran MaSen LiuGuo-Hao ZhangXiang-Yu GuoRui-Nan ZhaoXiao-Juan WuKai ZhangPeng GaoPublished in: Cell death & disease (2022)
Breast cancer (BC) is the most common malignant tumor in women worldwide. Metastasis is the main cause of BC-related death. The specific mechanism underlying BC metastasis remains obscure. Recently, PRSS22 was discovered to be involved in tumor development, however, its detailed biological function and regulatory mechanism in BC are unclear. Here, we characterized that PRSS22 expression is upregulated in BC tissues compared with non-tumorous breast tissues. Dual luciferase assays, bioinformatics analyses and chromatin immunoprecipitation (ChIP) assays indicated that transcription factor E2F1 directly binds to the PRSS22 promoter region and activates its transcription. Functionally, upregulation of PRSS22 promoted invasion and metastasis of BC cells in vitro and in vivo, whereas knockdown of PRSS22 inhibited its function. Mechanistically, the combination of PRSS22 and ANXA1 protein in BC cells was first screened by protein mass spectrometry analysis, and then confirmed by co-immunoprecipitation (Co-IP) and western blot assays. Co-overexpression of PRSS22 and ANXA1 could promote BC cell migration and invasion. We further demonstrated that PRSS22 promotes the cleavage of ANXA1 and in turn generates an N-terminal peptide, which initiates the FPR2/ERK signaling axis to increase BC aggressiveness.
Keyphrases
- transcription factor
- signaling pathway
- induced apoptosis
- gene expression
- mass spectrometry
- cell proliferation
- pi k akt
- high throughput
- poor prognosis
- cell cycle arrest
- dna binding
- dna methylation
- single cell
- type diabetes
- epithelial mesenchymal transition
- dna damage
- pregnant women
- mesenchymal stem cells
- south africa
- metabolic syndrome
- polycystic ovary syndrome
- high performance liquid chromatography